{
    "persona": "liberal",
    "model": "mixtral:8x7b-instruct-v0.1-q6_K",
    "topic": "healthcare",
    "language": "English",
    "text": "Exciting news for migraine sufferers! Long-term data shows atogepant's effectiveness in reducing monthly migraine days by 8.5 on average, maintaining a 50% reduction over 48 weeks. Safe, tolerable, and encouraging for patients & clinicians alike!",
    "retrieved_source": "https://www.medscape.com/viewarticle/first-long-term-data-atogepant-migraine-prevention-2024a10007cb",
    "annotation": {
        "topic": null,
        "persona": null,
        "authenticity": null
    },
    "id": "d2ca1c002e24bec20a38a94132bef80763735d8282d00094"
}